Результаты поиска

Appendiceal Adenocarcinoma Discovered During Acute Perforated Appendicitis: A Potential Contribution of Prophylactic CRS and HIPEC-A French BIGRENAPE Group Study.

BACKGROUND: Treatment of peritoneal metastasis (PM) from appendicular adenocarcinoma consists of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). No specific recommendation exists in case of acute appendicular syndrome (AAS) with perforated tumor. PATIENTS AND METHODS: Data from 12 expert centers from the BIG-RENAPE network were collected. We analyzed 5-year overall survival (OS), 5-year disease-free survival (DFS), and 5-year peritoneal-free survival (PFS) between carcinologic right colectomy (CRC) and prophylactic CRS with HIPEC (pCRS + HIPEC) groups. Survi…

Cytoreductive surgery without intra-peritoneal chemotherapy for metachronous colorectal peritoneal metastases.

BACKGROUND: Cytoreductive surgery and chemotherapy reportedly improve the prognosis of patients with metachronous peritoneal metastases. How … vival rate was 30.0% and the 5-year overall survival rate was 72.3%. None of the patients underwent hyperthermic intraperitoneal chemotherapy. The analysis indicated no potential risk factors for 5-year relapse-free survival. However, for 5-year overall survival, the multivariate analysis revealed that time to diagnosis of metachronous peritoneal metastases of < 2 years after primary surg …

Prognostic Factors of Long-Term Survival and Conditional Survival Analysis in MPM Patients Treated with CRS+HIPEC: A Retrospective Study of Two Centers.

OBJECTIVES: This study was designed to explore the survival benefit factors of malignant peritoneal mesothelioma (MPM) patients after cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) and to make dynamic survival prediction by conditional survival (CS). METHODS: Data of 212 patients with MPM who underwent CRS+HIPEC were retrospectively analyzed. Patients were divided into long-term survival (LTS) group (≥48.0 months) and short-term survival (STS) group (≤16.0 months) according to OS. Conditional survival is the probability of surviving y years after already su…

В ходе химиотерапии был обнаружен продвинутый первичный рак трубчатой трубки в множестве миеломы: отчет о деле и литература.

Множественная миелома (ММ) является общей злокачественной опухолью кровеносной системы, с другой стороны, заболеваемость раком фаллопийских трубок невелика, и на ее долю приходится лишь один случай: 0.1%~1.8% гинекологических злокачественных опухолей. Это крайне редкое явление. two Болезни, которые происходят вместе. В этой газете мы приводим случай первичного рака фаллопийских труб, который был обнаружен и метастазирован в яичник во время химиотерапии для MM, и мы анализируем литературу. ПРЕЗИДЕНТ: Пациент был 69 возраст и постменопаузальный период 19 Годы. Она была доставлена в больницу из-з

Совпадение в полном тексте источника
… Studies have shown that tumor cell reduction combined with Hyperthermic intraperitoneal chemotherapy (HIPEC) can improve patient survival outcomes [ 14 ]. … Kim SI Kim JW Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer ESMO Open 2021 6 3 100149 10.1016/j.esmoop.2021.100149 33984680 PMC8314869 Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. …

Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma: Canadian practices and outcomes.

INTRODUCTION: Peritoneal mesothelioma (PM) is a rare malignancy originating from the peritoneal lining. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is the standard-of-care for patients with isolated PM. Due to a paucity of prospective data there are several different HIPEC protocols. The aims of this study are to describe the CRS and HIPEC protocols for PM and patient outcomes across Canada. METHODS: A multicenter retrospective study was performed on patients diagnosed and treated for PM with CRS and HIPEC in four major peritoneal disease centers in Canada betw

Patterns and Timing of Recurrence following CRS and HIPEC in Colorectal Cancer Peritoneal Metastasis.

INTRODUCTION: Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) is an established treatment of Colorectal Peritoneal Metastases (CRPM). This study aims to determine the timing and patterns of recurrent disease on imaging following complete CRS/HIPEC. METHODS: Retrospective analysis of a national peritoneal tumour service database identified CRPM patients with complete CRS/HIPEC(CC0) from 2005 to-2018. Patients with<2 years follow-up or and those where post-operative histology from the CRS/HIPEC procedure did not confirm CRPM from their original colorectal cancer …

Consensus statement and clinical pathway for the management of colon cancer with peritoneal metastases in the state of Delaware.

BACKGROUND: Increasing data suggests that the combination of modern systemic therapies and Cytoreductive surgery with or without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) may improve the outcome of patients with colon cancer with peritoneal metastases. Patient selection and sequence of treatments remains ill-defined. MATERIALS AND METHODS: A working group, the State of Delaware Peritoneal Surface Malignancies Task Force (DE-PSM-TF), was created including representatives from medical and surgical oncology from the acute care hospitals in Delaware. An extensive review of all available l…

Urinary and fecal incontinence in patients with advanced ovarian cancer treated with CRS + HIPEC.

PURPOSE: The objective of this work was to analyze the long-term prevalence of urinary and fecal incontinence and their impact on quality of life in patients with advanced and recurrent ovarian cancer treated with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy (CRS + HIPEC). METHODS: This cross-sectional study included a series of patients with advanced and recurrent ovarian cancer treated by CRS + HIPEC, with a disease-free period of at least 12 months after the procedure. Urinary incontinence was evaluated using the International Consultation on Incontine

Asymptomatic peritoneal carcinomatosis originating from benign cystic peritoneal mesothelioma.

Benign multicystic mesothelioma is a rare tumour that originates from the abdominal peritoneum with a predisposition to the pelvic peritoneu … sidered the treatment of choice and is based on the removal of the cysts from the abdominal cavity. Hyperthermic intraperitoneal chemotherapy can be considered as a primary treatment in patients with recurrences or even as a part of primary treatment associated with surgery. Survival at 5 years is 100% and invasive or malignant progression is extraordinary. The treatment approach should b …

Narrative review of malignant ascites: epidemiology, pathophysiology, assessment, and treatment.

BACKGROUND AND OBJECTIVE: Malignant ascites (MA) is common in patients with advanced cancer, and about 60% of patients with MA experience di … rst lines of treatment. Intraperitoneal drug administration (catumaxomab, bevacizumab, aflibercept, hyperthermic intraperitoneal chemotherapy, triamcinolone), indwelling peritoneal catheters, peritoneovenous shunting, and cell-free and concentrated ascites reinfusion therapy are commonly used to manage refractory ascites. A new device for this purpose is alfapump, which transfers ascites …

Colobronchial fistula: the pathogenesis, clinical presentations, diagnosis and treatment.

BACKGROUND: Colobronchial fistula (CBF) is rare and easy to be delayed in clinic. There is no systemic study about this disease. The pathoge … matic hernia, pulmonary infection or abscess, colonic malignancy, colonic interposition, radiation, hyperthermic intraperitoneal chemotherapy (HIPEC), diaphragmatic mesh repair, pulmonary tuberculosis and pyonephrosis. Based on the anatomical location and the causes of fistula, CBF were divided into four types: type I, CBF secondary to the adhesion among colon, diaphragm and lung; type II …

Impact of extent of parietal peritonectomy on oncological outcome after cytoreductive surgery and HIPEC.

BACKGROUND: In peritoneal surface malignancy (PSM), in spite of optimal cytoreductive surgery (CRS), majority of recurrences that occur are … peritonectomy (TPP) or involved field peritonectomy (IFP) as a part of the procedure during CRS and hyperthermic intraperitoneal chemotherapy (HIPEC). METHODS: This was a retrospective analysis of prospectively collected data, from February 2013 to December 2017. A total of 163 patients with PSM underwent TPP or IFP with CRS plus HIPEC. Their oncological outcomes, recurrence pattern, pos …

Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model.

BACKGROUND: Pemetrexed is a systemic chemotherapeutic agent used in the treatment of malignant mesothelioma. This drug represents a potentially promising intraperitoneal (IP) agent to use for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal mesothelioma. However, this has yet to be supported by preclinical studies. Therefore, we aimed to study the effect of pemetrexed dose and perfusion temperature on the resultant pemetrexed concentration in 3 different compartments (systemic circulation, portal circulation and peritoneal tissues) using a murine model. METHODS…

Prognostic value of preoperative serum C-reactive protein level for survival in mucinous appendix cancer treated with complete CRS/HIPEC.

BACKGROUND: The role of systemic inflammation, a significant prognostic factor in various malignancies, is underexplored in mucinous appendix cancer (MAC). We assessed how inflammation, expressed by preoperative serum C-reactive protein (CRP), correlates with survival across MAC histopathologies managed with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). METHODS: This retrospective cohort study included MAC patients with peritoneal dissemination, who had complete CRS/HIPEC (CC-0/1) (1998-2023). Preoperative serum CRP cut-off was defined with the minimum p-val…

Cytoreductive surgery and HIPEC: A 10-year single-center retrospective cohort study.

BACKGROUND AND AIMS: The combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is widely used to treat pseudomyxoma peritonei (PMP), peritoneally metastasized colorectal or appendiceal cancer (pmCRC or pmAppCa) and peritoneal mesothelioma, although the specific efficacy of HIPEC remains inadequately proven. The aim of this retrospective study was to evaluate the outcomes of our CRS-HIPEC procedures and compare them with prior reports. MATERIALS AND METHODS: All patients operated with the intent of CRS-HIPEC at Oulu University Hospital (OUH) between S…

A Retrospective Examination of Neoadjuvant Chemotherapy for Metachronous Colorectal Peritoneal Metastases Prior to CRS/HIPEC.

BACKGROUND: Neoadjuvant chemotherapy (NACT) prior to cytoreductive surgery (CRS) and heated intraperitoneal chemoperfusion (HIPEC) for patients with metachronous colorectal peritoneal metastases (CRPM) carries theoretical advantages but thus far has not demonstrated survival benefit. METHODS: We conducted a retrospective single institution study of patients with CRPM undergoing CRS/HIPEC ± NACT from 2002 to 2022. RESULTS: A total of 199 patients with metachronous CRPM were identified; 128 patients (64.3%) underwent NACT while 71 patients (35.7%) underwent upfront CRS/HIPEC. The majority of p

Do Lymph Node Metastases Matter in Appendiceal Cancer with Peritoneal Carcinomatosis? A US HIPEC Collaborative Study.

BACKGROUND: Whether formal regional lymph node (LN) evaluation is necessary for patients with appendiceal adenocarcinoma (AA) who have peritoneal metastases is unclear. The aim of this study was to evaluate the prognostic value of LN metastases on survival in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC). METHODS: A retrospective analysis of the US HIPEC collaborative, a multi-institutional consortium comprising 12 high-volume centers, was performed to identify patients with AA who underwent CRS-HIPEC with adequate LN sampling (≥ 12 LNs)…

External validation of the Pre-operative Predictive (PROP) score for feasibility of complete cytoreduction in colorectal peritoneal metastases: a single-centre experience.

PURPOSE: Colorectal peritoneal metastases (PM) remain a major therapeutic challenge. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) offers prolonged survival in selected patients. Accurate preoperative assessment of resectability is crucial to avoid non-beneficial surgery. The Preoperative Predictive Score (PROP) integrates nine preoperative clinical and radiologic parameters to predict the completeness of cytoreduction (CC). This study aimed to externally validate the PROP Score in an independent European single-centre cohort. METHODS: 63 Patients…

Systematic total parietal peritonectomy for peritoneal mesothelioma-perioperative and oncological outcomes in an Indian cohort of 100 patients.

BACKGROUND AND AIM: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is the current standard of care for patients with peritoneal mesothelioma (PeM). In this retrospective study, we evaluate the perioperative and oncological outcomes of systematic total parietal peritonectomy (TPP) which has demonstrated a significant improvement in survival compared to selective parietal peritonectomy. METHODS: 100 patients with PeM treated by CRS-HIPEC from 1st January 2013 to 31st December 2022 at three high-volume peritoneal malignancy centers were included. All patients u…

Surgery for Colorectal Peritoneal Metastases in non-expert centers is strongly associated with tumor persistence or early recurrence: a bicentric study of 106 patients.

BACKGROUND: Complete cytoreductive surgery (CRS) performed in expert centers is a key determinant of outcome in patients with colorectal peritoneal metastases (CRPM). In the contemporary context of ongoing debate regarding the role of HIPEC following the PRODIGE 7 trial, the impact of initial management outside expert centers on outcomes remains insufficiently characterized. This study evaluates the value of systematic second-look surgeries in expert centers after CRS in non-expert centers. METHODS: Patients with histologically confirmed CRPM who initially underwent surgery in non-expert cent